High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I

We investigated the prevalence of preexisting M184V/I and associated risk factors among clinical trial participants with suppressed HIV and evaluated the impact of M184V/I on virologic response after switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). DESIGN: Participant data wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Sax, Paul E., Andreatta, Kristen, Molina, Jean-Michel, Daar, Eric S., Hagins, Debbie, Acosta, Rima, D’Antoni, Michelle L., Chang, Silvia, Martin, Ross, Liu, Hui, Blair, Christiana, McNicholl, Ian, Gallant, Joel, Collins, Sean E., Martin, Hal, White, Kirsten L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451915/
https://www.ncbi.nlm.nih.gov/pubmed/35466963
http://dx.doi.org/10.1097/QAD.0000000000003244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451915/
https://www.ncbi.nlm.nih.gov/pubmed/35466963
http://dx.doi.org/10.1097/QAD.0000000000003244

Ejemplares similares